De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer.
Epistemonikos ID: 038f822c1685d6d1934b0951e9d1cd452d5dd7cb
First added on: Oct 09, 2026